Enspryng for Neuromyelitis Optica Spectrum Disorder Approved in EU

The European Commission recently approved of Enspryng for neuromyelitis optica spectrum disorder (NMOSD). Now, European patients have a new treatment option. This one is especially useful as it can be self-administered at home.


NMOSD is a rare and chronic disease that is characterized by inflammation of the spinal cord and optic nerve. Affected individuals experience symptoms in the form of attacks, which are followed by periods of remission. Symptoms include eye pain, vision loss, paralysis of the lower limbs, sensory loss, pain in the limbs/spine, stiffness, headaches, changes in deep tendon reflex, diminished bowel and bladder control, and back pain. Doctors don’t know what causes these symptoms; they are only aware that NMOSD is an autoimmune condition. This means that the immune system mistakenly attacks the body.

There are currently three FDA-approved options for NMOSD: Uplinza, Enspryng, and Soliris. In addition, doctors will utilize high doses of corticosteroids and plasma exchange for patients experiencing an attack. Immunosuppressive drugs are also used. Other medications may be prescribed to address other symptoms as well.

EC Approval for Enspryng

According to Roche, the EC approved of Enspryng for the treatment of NMOSD. European patients may now utilize this at-home injection to treat their condition. The EC’s decision comes after the FDA’s approval, which was granted last August. When this occurred, Enspryng joined Soliris and Uplinza to become the third FDA-approved option for NMOSD.

You can find the source article here.

Share this post

Share on facebook
Share on twitter
Share on linkedin
Share on pinterest
Share on print
Share on email